Poster 51

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Evaluation of Creatine Phosphokinase Elevations in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Authors: Mark Lebwohl, Bruce Strober, Thomas Scharnitz, Misti Linaberry, Kim Hoyt, Subhashis Banerjee, Renata M. Kisa, George Martin

< PREVIOUS POSTER NEXT POSTER >

POSTER 51